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Background: Human Papillomavirus (HPV) in cervical epithelium has been identified as the main etiological factor
in the developing of Cervical Cancer (CC), which has recently become a public health problem in Mexico. This
finding has allowed for the development of vaccines that help prevent this infection. In the present study, we
aimed to determine the prevalence and HPV type-distribution in Mexican women with CC, high-grade squamous
intraepithelial lesion (HSIL), low-grade squamous intraepithelial lesion (LSIL), and Normal cytology (N) to estimate
the impact of the HPV vaccines.
Methods: The PubMed database was used to identify and review all articles that reported data on HPV prevalence
in CC, precursor lesions, and normal cytology of Mexican women.
Results: A total of 8,706 samples of the tissues of Mexican women were stratified according to diagnosis as follows:
499 for CC; 364 for HSIL; 1,425 for LSIL, and 6,418 for N. According to the results, the most prevalent genotypes are
the following: HPV16 (63.1%), -18 (8.6%), -58, and −31 (5%) for CC; HPV-16 (28.3%), 58 (12.6%), 18 (7.4%), and 33
(6.5%) for HSIL; HPV-16 (13.1%), 33 (7.4%), 18 (4.2%), and 58 (2.6%) for LSIL, and HPV-16 (3.4%), 33 (2.1%), 18, and 58
(1.2%) for N.
Conclusions: Taken together, genotypes 58 and 31 (10%) are more common than type 18 (8.6%) in CC. Therefore,
the inclusion of these two genotypes in a second-generation vaccine would provide optimal prevention of CC in
Mexico.
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Cervical cancer (CC) is one of the main causes of death in
women in developing countries [1]. In 2008, an estimate
of 10,186 Mexican women developed Cervical Cancer
(CC) and 5,061 died as a result of this disease [2]. The role
of the Human papillomavirus (HPV) in the etiology of CC
precursor lesions and invasive carcinoma development
has been well established. Persistent infection with High-
Risk HPV (HR-HPV) types has been recognized as a factor
for CC development [3]. Highlighting the HR-HPV types* Correspondence: maosal89@yahoo.com
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distribution, and reproduction in any medium16 and 18 are associated with over 70% of CC worldwide
[4] being the most frequent HPV16.
There are previous meta-analysis papers, which report
information on the HPV-type prevalence distribution in
precursor lesions and CC worldwide [5-8]. However, these
data are variable and incomplete for Mexican population.
A recent meta-analysis that included 115,789 HPV-
positive female samples of precursor lesions and CC, HPV
types 16, 18, and 45 presented different prevalence rates,
and they comprised the most common viral types in CC
worldwide [7]. The HPV16 type is also the most common
genotype in normal cytological samples from healthy
women worldwide [8]. Regional data on type-distribution
is essential for estimating the impact of vaccines on CC
and for the development of screening programs.ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.infectagentscancer.com/content/7/1/34In order to have a possible HPV status in Mexico, the
most complete of the already published data on cervical
lesions and normal cytology were reviewed.
Results
Review of the HPV prevalence
In the present report, we analyzed the HPV prevalence
from 12 already published reports that met the afore-
mentioned criteria. There were a total of 8,706 cases, of
which 499 were identified as CC, 364 as HSIL, 1,425 as
LSIL, and 6,418 as N. Overall, HPV prevalence was 95,
75.5, 42, and 15%, respectively (Figure 1). In CC, HPV-
16 (63.1%), -18 (8.6%), -58, and −31 (5%) were the most
prevalent types, while for HSIL, these were HPV-16
(28.3%), -58 (12.6%), -18 (7.4%), and −33 (6.5%), for
LSIL, HPV-16 (13.1%), -33 (7.4%), -18 (4.2%), and −58
(2.6%) and for cases with normal cytology, these were
HPV-16 (3.4%), -33 (2.1%), -58 and −18 (1.2%) (Table 1)
(Figure 2).
HPV-16 was the most prevalent type in each cervical
lesion and in normal cytology (Figure 3). In summary,
the HPV-16/18 fraction was the most prevalent in CC,
while in HSIL, the HPV-16/58 fraction was the most
prevalent; for both low-grade lesions and normal tis-
sue, the HPV-16/33 fraction was the most prevalent
(Table 1).
In CC, there were variations in HPV type prevalence
in the Western, Central and South regions of Mexico. InFigure 1 HPV prevalence in Mexican women. The HPV prevalence is exp
HPV. From 8,706 samples of Mexican women, 476/499 were positive for HP
positive for HPV and LSIL, 967/6,418 were positive for HPV and cytology nothe West region, HPV-16 and −58 were followed by −18
and −33. In the Central region, the same behavior was
observed on HPV types −16, -18, -45, and −58, while the
South region shows prevalence on HPV types −16, -18,
-31, and −58 (Table 2). There was no variation in HPV
prevalence for HSIL cases in the West and Central
regions, where HPV-16, -58, and −18, were found, while
types −16, -33, and −58 were found in the South region.
In N cases, findings show the most drastic variation in
HPV prevalence of the three regions. The West region
shows HPV prevalence for types −16, -58, and −18; in
the Central region, for types −16, -18, and 31; and in the
South for types −16, -33, and −58 (Table 2).
The differences in HPV prevalence for each group
(CC, HSIL, LSIL, and normal) were assessed by contin-
gency tables and the x2 test. The most prevalent geno-
types in each type of cervical lesion and normal cytology
were statistically associated with the pathological diagno-
sis (p <0.05) (Table 3). The difference in the prevalence
of HPV16, -33, -45, and 58 between CC and HSIL was
very significant (p = 0.000), while in HPV18 and 31 it
was not (p >0.05) (Table 3). The statistical difference for
HPV16, -18, -31, -33, -45, and −58 between CC and
LSIL was significant. (p <0.05) (Table 3). The difference
of HPV16, -18, -31, -45, and −58 between CC and nor-
mal cytology was statistically significant (p <0.05), but
in HPV33, the difference was not statistically significant
(p >0.05) (Table 3).ressed as percentage of all cases submitted to molecular detection of
V and CC, 275/364 were positive for HPV and HSIL, 601/1,425 were
rmal.
Table 1 Overall prevalence of HPV types found in Mexican women according to type of lesion and normal cytology
Type CC HSIL LSIL Normal All
HPV n % N % N % N % N %
6* 5 1.00 3 0.82 35 2.46 26 0.41 69 0.79
11* 2 0.40 4 1.10 9 0.63 39 0.61 54 0.62
13*** 0 0.00 0 0.00 1 0.07 1 0.02 2 0.02
16** 315 63.13 103 28.30 188 13.19 221 3.44 827 9.50
18** 43 8.62 27 7.42 61 4.28 78 1.22 209 2.40
26*** 0 0.00 1 0.27 0 0.00 0 0.00 1 0.01
31** 25 5.01 20 5.49 21 1.47 39 0.61 105 1.21
32*** 0 0.00 0 0.00 2 0.14 4 0.06 6 0.07
33** 5 1.00 24 6.59 106 7.44 138 2.15 273 3.14
34*** 0 0.00 0 0.00 0 0.00 2 0.03 2 0.02
35** 2 0.40 2 0.55 5 0.35 12 0.19 21 0.24
39** 4 0.80 4 1.10 2 0.14 12 0.19 22 0.25
40* 0 0.00 0 0.00 1 0.07 5 0.08 6 0.07
42* 0 0.00 1 0.27 0 0.00 1 0.02 2 0.02
44*** 0 0.00 0 0.00 0 0.00 1 0.02 1 0.01
45** 20 4.01 3 0.82 28 1.96 32 0.50 83 0.95
51** 1 0.20 4 1.10 5 0.35 12 0.19 22 0.25
52** 6 1.20 2 0.55 8 0.56 14 0.22 30 0.34
53*** 2 0.40 2 0.55 16 1.12 59 0.92 79 0.91
54* 0 0.00 0 0.00 2 0.14 5 0.08 7 0.08
55*** 0 0.00 1 0.27 0 0.00 0 0.00 1 0.01
56** 3 0.60 7 1.92 6 0.42 3 0.05 19 0.22
57*** 0 0.00 0 0.00 0 0.00 2 0.03 2 0.02
58** 25 5.01 46 12.64 38 2.67 79 1.23 188 2.16
59** 5 1.00 5 1.37 7 0.49 12 0.19 29 0.33
61* 0 0.00 2 0.55 8 0.56 33 0.51 43 0.49
62*** 0 0.00 0 0.00 9 0.63 15 0.23 24 0.28
66*** 1 0.20 5 1.37 7 0.49 13 0.20 26 0.30
67*** 2 0.40 1 0.27 0 0.00 0 0.00 3 0.03
68** 1 0.20 0 0.00 0 0.00 8 0.12 9 0.10
69*** 9 1.80 0 0.00 4 0.28 6 0.09 19 0.22
70* 0 0.00 2 0.55 4 0.28 24 0.37 30 0.34
71*** 0 0.00 0 0.00 6 0.42 17 0.26 23 0.26
72* 0 0.00 0 0.00 1 0.07 3 0.05 4 0.05
73** 0 0.00 2 0.55 0 0.00 1 0.02 3 0.03
81* 0 0.00 4 1.10 10 0.70 28 0.44 42 0.48
82** 0 0.00 0 0.00 1 0.07 1 0.02 2 0.02
83*** 0 0.00 0 0.00 4 0.28 6 0.09 10 0.11
84*** 0 0.00 0 0.00 4 0.28 2 0.03 6 0.07
85*** 0 0.00 0 0.00 0 0.00 3 0.05 3 0.03
87*** 0 0.00 0 0.00 0 0.00 1 0.02 1 0.01
89*** 0 0.00 0 0.00 1 0.07 4 0.06 5 0.06
90*** 0 0.00 0 0.00 0 0.00 4 0.06 4 0.05
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Table 1 Overall prevalence of HPV types found in Mexican women according to type of lesion and normal cytology
(Continued)
97*** 0 0.00 0 0.00 0 0.00 1 0.02 1 0.01
102*** 0 0.00 0 0.00 1 0.07 0 0.00 1 0.01
negatives 23 4.61 89 24.45 824 57.82 5,451 84.93 6,387 73.36
Total 499 100.00 364 100.00 1,425 100.00 6,418 100.00 8,706 100.00
n = number of samples; %: frequency; CC: cervical carcinoma, HSIL: high-grade squamous intraepithelial lesion, LSIL: low grade squamous intraepithelial lesion,
Normal: Women without lesion and normal cytology. *: HPV Low risk (no oncogenic potential); **: HPV high risk (oncogenic potential); ***: HPV without sufficient
epidemiological evidence to know their risk of oncogenesis [2].
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tween CC and HSIL was 4.3, and increased between CC
and LSIL (11.9) and between CC and normal (49.1)
(Table 3). The RR of HPV-18 infection between CC and
HSIL was 1.1 and increased between CC and LSIL (2.1)
and between CC and normal (7.7) (Table 3). The RR of
HPV-31 infection between CC and HSIL was 0.9, and
increased between CC and LSIL (3.5) and between CC
and normal (8.6) (Table 3). RR of HPV-58 infection rela-
tive risk between CC and HSIL was 0.3, and also
increased between CC and LSIL (1.9) and between CC
and normal (4.2) (Table 3). RR of HPV-33 infection be-
tween CC and HSIL and LSIL is balanced (0.1), but
increased slightly between CC and normal (0.4) (Table 3).
RR of HPV-45 infection between CC and HSIL was 5
and decreased between CC and LSIL (2), but increased
between CC and normal (8.3) (Table 3). In summary, the
RR of HPV-16, -18, -31, and −58 infection increased be-
tween CC and precursor lesions and normal cytology,Figure 2 A. HPV prevalence in women with normal cytology. B. HPV p
HSIL. D. HPV prevalence in women with CC. *: Low risk HPV (no oncogenic
sufficient epidemiological evidence to know their risk of oncogenesis (2).but HPV-33 and −45 did not increase between CC and
precursor lesions and normal cytology (Table 3).
Discussion
The development of cervical cancer is associated with the
oncogenic HPV infection. These viruses contain early activ-
ity genes in its genome (E1, E2, E4, E5, E6, and E7) and late
activity genes (L1, L2). The molecular evidence indicates
that the oncogenic HPV proteins E6 and E7 are responsible
for the inactivation of certain cell cycle regulatory proteins,
such as p53 and pRb, respectively. The uncontrolled prolif-
erative cellular activity that characterizes cells transformed
by oncogenic HPV infection in CC and other cancers asso-
ciated with this infection is due to the loss-of-function of
proteins that arrest the cell cycle. Thus, this infection with
oncogenic HPV results must play a central role in the de-
velopmental model of the CC [1].
The present meta-analysis helped to know the HPV
prevalence and type-distribution in several regions ofrevalence in women with LSIL. C. HPV prevalence in women with
potential); **: high risk HPV (oncogenic potential); ***: HPV without
Figure 3 Comparison of the most common HPV genotypes in each type of cervical lesion and normal cytology. HPV prevalence (types
16, 18, 58, 31, 33 and 45) in each type of cervical lesion and normal cytology. The genotypes analyzed correspond to the high risk and are most
frequently found in cervical epithelium.
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http://www.infectagentscancer.com/content/7/1/34Mexico. From the total of the published reports, only 12
were included in the final meta-analysis, representing
the 23.5% of the reports on HPV in Mexico [9-20]. In
CC, the most common HPV types found were both
HPV-16 and −18 (71.7%), with a similar prevalence to
that reported worldwide. However, when performing a
regional analysis, differences in the prevalence of this
fraction in three regions (Central, South, and West) of
Mexico were found. While in the Central and South
regions, the HPV-16/18 fraction is the most prevalent,
in the West region, the HPV-16/58 fraction is the most
prevalent, with a percentage of 90.3 (Table 2). Thus, in
this region there is a different HPV prevalence than that
of reports worldwide. It is noteworthy that in women
with high-grade lesions, HPV-58 is found as the second
most prevalent (8.8%), followed by HPV18 (6.5%) and
−31 (2.5%). The case of HPV-58 is quite similar to that
of women of Southeast Asia (China, Japan) [21,22]. We
hypothesized that there is a probability of finding genetic
components that influence the infection by means of an
“Asian HPV type” in Mexican population. In summary,
with respect to the HPV-58 infection, we can mention
that this HPV is common in Mexican population, its dis-
tribution is delimited to certain geographical regionsTable 2 Regional distribution of HPV infection in positive wo
Region West
Central
n n (141) n (18) n (11) n (187) n (183)
HPV type N (%) HSIL (%) CC (%) N (%) LSIL (%)
16 24.1 50 72.7 17.1 50.8
18 7.1 5.6 9.1 17.1 25.1
31 4.3 0 0 6.9 4.3
33 5.7 0 0 5.3 0
45 5.7 0 0 2.1 2.7
58 12.8 33.3 18.2 6.9 2.7
HPV prevalence percentages in three regions of Mexico (west, central and south reg(southern Mexico) and, by their high frequency in nor-
mal smears and precursor lesions, its infection possesses
a high probability of leading to the progression of inva-
sive lesions. Thus, there are necessary additional studies
that might explain the biological differences between
HPV-16 and −58 infections and the progression of cer-
vical cancer.
Recently, an HPV immunization scheme was intro-
duced in some countries, including Mexico. The strategy
proposed for Mexico includes primary prevention with
HPV vaccination for girls aged between 9 and 16 years
(prior to sexual initiation). However, in some regions of
Mexico, other genotypes that are not considered within
this scheme are detected with high frequency. For ex-
ample, the HPV-31 type is the second most common
one in the states of Guanajuato and San Luis Potosí [9]
(West region), and genotype 58 is the second most fre-
quent in Yucatan [10] (South region). The high preva-
lence of HR-HPV types not present in current vaccines
could be an important factor to consider within the
strategies and policies of CC prevention.
On the other hand, with this type of vaccines, the rate
of CC mortality is expected to be reduced. In general,
Mexico currently has a mortality rate by CC of 9.2,man
South
n (94) n (161) n (617) n (418) n (162) n (304)
HSIL (%) CC (%) N (%) LSIL (%) HSIL (%) CC (%)
48.9 57.2 22.2 22.7 29.6 65.7
12.7 8 5.5 3.5 8.6 8.8
6.3 2.1 3.2 3.1 14 6.9
3.1 0.5 19.4 25.3 21 1.3
1 4.3 3.2 5.5 1.2 3.9
14.8 2.7 7.8 7.8 16 5.9
ion).
Table 3 HPV prevalence analysis in CC, HGSIL, LGSIL and normal cytology
Type CC (%) n=499 HSIL (%) n=364 CC/HSIL PR (RR; 95% CI) p LSIL (%) n=1,425 CC/LSIL PR (RR; 95% CI) p Normal (%) n=6,418 CC/Normal PR (RR; 95% CI) p
Overall 476 (95.3) 275 (75.5) 1.2 (6.7; 1.86-3.88) 0.000 601 (42.1) 2.2 (28.3; 1.78-4.04) 0.000 997 (15.5) 6.1 (113.5; 1.77-4) 0.000
16 315 (63.1) 103 (28.3) 2.2 (4.3; 2.1-3.44) 0.000 188 (13.1) 4.8 (11.9; 2.30-3.13) 0.000 221 (3.4) 18.5 (49.1; 2.28-3.16) 0.000
18 78 (1.2) 27 (7.4) 0.1 (1.1; 2.21-3.27) 0.522 61 (4.2) 0.2 (2.1; 2.2-3.28) 0.000 78 (1.2) 1 (7.7; 2.08-3.46) 0.000
31 25 (5) 20 (5.4) 0.9 (0.9; 2.05-3.51) 0.752 21 (1.4) 3.5 (3.5; 2.03-3.56) 0.000 39 (0.6) 8.3 (8.6; 1.95-3.7) 0.000
33 5 (1) 24 (6.5) 0.1 (0.1; 1.21-5.98) 0.000 106 (7.4) 0.1 (0.1; 1.14-6.34) 0.000 138 (2.1) 0.4 (0.4; 1.13-6.38) 0.083
45 20 (4) 3 (0.8) 5 (5; 2.26-3.18) 0.004 28 (1.9) 2.1 (2; 1.9-3.8) 0.012 32 (0.5) 8 (8.3; 1.89-3.82) 0.000
58 25 (5) 46 (12.6) 0.3 (0.3; 1.95-3.7) 0.000 38 (2.6) 1.9 (1.9; 1.96-9.7) 0.011 79 (1.2) 4.1 (4.2; 1.89-3.81) 0.000
Differences in prevalence of HPV16, 18, 31, 33, 45 and 58 in each type of cervical lesion and normal cytology. The genotypes analyzed correspond to the high risk and are most frequently found in cervical epithelium.
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http://www.infectagentscancer.com/content/7/1/34which is lower than that of the South region considered
in this analysis (12.2) and higher than that reported in
the Central region (8.0) (Mortality in Women, Mexican
Ministry of Health 2010). In this analysis, we found the
highest prevalence in the South region for HPV-16 and
−58 (76.7%).
Further studies of HPV testing are necessary to ascer-
tain the real impact of the current vaccines, primarily
because of the different HPV types found.
Conclusions
HPV prevalence in Mexican women is heterogeneous
according to lesion type and region. Thus, while for
CC the most common HPV types are HPV-16 and
−18 in high-grade lesions, the HPV-16 and −58 types
are more frequent. Finally, in low-grade lesions and
normal cytology, the most common genotypes were
HPV-16 and −33.
According to the present analysis, a potential new-
generation vaccine directed against groups A7 and −9
papillomavirus would protect our population in approxi-
mately 90% of cases. This would provide optimal preven-
tion of CC in Mexico (and in the Asian region).
Furthermore, this approach could serve as a base to pro-
mote new screening methods directed toward the most
frequent HPV types.
Methods
Inclusion criteria and study selection
The PubMed database (National Library of Medicine,
Bethesda, MD, USA) was used to identify articles pub-
lished up to 2012 that had the combination of medical
terms with the heading “Human papillomavirus” or
“HPV” and “cervical cancer” or “cervical neoplasia” or
“cervical intraepithelial neoplasia” and “Mexico”. We
selected and reviewed all articles that reported data on
HPV prevalence in CC, precursor lesions, and normal
cytology of Mexican women. The analysis was restricted
to studies that have the following inclusion criteria: a)
that the samples analyzed were of Mexican women
(cared for at any national health system, including the
Mexican Institute of Social Security (IMSS), the Mexican
Institute of Social Security Services of State Workers
(ISSSTE), the Mexican Ministry of Health (SSa), and the
Mexican Ministry of National Defense (SEDENA); b)
that the report contained a clear description of the path-
ology or cytology and classification determined as CC
(squamous cell carcinoma and adenocarcinoma, taken as
two separate entities); high-grade squamous intraepithe-
lial lesion (HSIL) according to the Bethesda system, or
Cervical intraepithelial neoplasia 2 or 3 (CIN2, CIN3);
Low-grade squamous intraepithelial lesion (LSIL), or
Cervical intraepithelial neoplasia 1 (CIN1) and normal
cytology; c) that the report included at least one of thefour classifications: CC; HSIL or CIN2/CIN3 alterna-
tively, LSIL, or CIN1, normal, and that the number of
samples included in the report was >10, and d) that the
detection method comprised at least viral genotypes 16,
18, and some others, and that it would be conducted
by 1) Polymerase chain reaction [PCR]+direct sequen-
cing, or 2) PCR+restriction fragment length polymorph-
isms, or 3) PCR+reverse line blot.
A search of the literature identified 51 studies, of
which only 12 could be included in the final meta-ana-
lysis. Exclusion criteria were the following: a) only
HPV16 and −18 genotypes were studied; b) HPV type
was not specified (hybrid capture); c) number of cases
was carried out for <10; d) a method other than PCR
was used to detect HPV types, e) the histological cat-
egory was not reported as normal, LSIL, HSIL, or CC.
Estimation of HPV prevalence
Overall, HPV prevalence was estimated by dividing the
total number of subjects for each histological group by
the number of HPV-positive cases. Type-specific HPV
prevalence is presented for each histological classifica-
tion for all HPV types identified. Multiple infections
were not considered in this analysis.Statistical analysis
The differences in HPV prevalence for each group (CC,
HSIL, LSIL, and normal) were assessed by contingency
tables. The x2 test was conducted and considered of statis-
tical significance with a level of p <0.05. Type-specific
HPV prevalence was compared between HSIL/LSIL/nor-
mal and CC by Prevalence ratios (PR) and Relative risk
(RR) with 95% Confidence intervals (95% CI). The ana-
lyses were performed by SPSS v15 software.
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